Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Holding IMRX?
Track your performance easily
IMRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $9.00
Previous Close$2.28
Volume4.06M
Average Volume (3M)5.66M
Market Cap
$67.61M
Enterprise Value$12.19M
Total Cash (Recent Filing)$59.73M
Total Debt (Recent Filing)$4.31M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 07, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding29,653,355
10 Day Avg. Volume25,831,212
30 Day Avg. Volume5,659,555
Standard Deviation0.39
R-Squared0.00654
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.02
Price to Sales (P/S)4293.56
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue635.06
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$14.25Price Target Upside488.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Immuneering News
PremiumMarket News
3 Penny Stocks to Watch Now, 9/18/24
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInitial Phase 2a data for IMM-1-104 + modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer included a complete response in the first patient.
Regulatory DesignationIMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma, was granted Fast-Track Designation by the FDA.
Safety ProfileThe combination appears to be well-tolerated with no grade 4 TRAEs and only 1 grade 3 rash reported.
Bears Say
Clinical TrialsThe phase I dataset did not increase confidence that IMM-1-104 or its mechanism of action can drive clinically meaningful regressions.
Drug EfficacyPatient 1, who achieved a complete response, did not have a KRAS mutation, raising questions about how representative the result is.
Financial PerformanceIMRX reported an EPS of -$0.47 for 2Q24, mostly in-line with consensus of -$0.52 with slightly higher R&D.
---
Ownership Overview
29.65% Insiders
16.40% Mutual Funds
7.11% Other Institutional Investors
46.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.00 and its highest was $9.00 in the past 12 months.
What is Immuneering’s market cap?
Currently, no data Available
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Aug 06, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.05.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -$0.55.
How many shares outstanding does Immuneering have?
Immuneering has 29,653,355 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went down -8.065%.
Which hedge fund is a major shareholder of Immuneering?
Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at N/A.
---
Immuneering Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (488.84% Upside)
$14.25 (488.84% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 681.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.24%
12-Months-Change
Fundamentals
Return on Equity
-61.81%
Trailing 12-Months
Asset Growth
-38.28%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
---
IMRX Stock 12 Month Forecast
Average Price Target
$14.25
▲(488.84% Upside)
Technical Analysis
Best Analysts Covering IMRX
1 Year
---